$ALLO

Allogene Therapeutics, Inc.

CIK:0001737287|SEC Filings

Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Income Statement [Abstract]
Collaboration revenue - related party	$ 4,640	$ 0	$ 4,640	$ 0
Operating expenses:
Research and development	30,721	40,156	62,724	90,356
General and administrative	20,839	14,281	34,928	29,272
Impairment of long-lived assets	0	2,382	0	2,382
Total operating expenses	51,560	56,819	97,652	122,010
Loss from operations	(46,920)	(56,819)	(93,012)	(122,010)
Other income (expenses), net:
Interest and other income, net	4,647	6,187	8,220	11,703
Interest expense	(343)	(268)	(643)	(418)
Other income (expenses), net	(61)	(43)	151	49
Total other income (expenses), net	4,243	5,876	7,728	11,334
Net loss	(42,677)	(50,943)	(85,284)	(110,676)
Other comprehensive income (loss):
Net unrealized gain (loss) on available-for-sale investments	(335)	(88)	(787)	44
Net comprehensive loss	$ (43,012)	$ (51,031)	$ (86,071)	$ (110,632)
Net loss per share, basic (in dollars per share)	$ (0.13)	$ (0.23)	$ (0.30)	$ (0.51)
Net loss per share, diluted (in dollars per share)	$ (0.13)	$ (0.23)	$ (0.30)	$ (0.51)
Weighted-average number of shares used in computing net loss per share, basic (in shares)	328,930,269	218,929,548	284,855,386	217,153,948
Weighted-average number of shares used in computing net loss per share, diluted (in shares)	328,930,269	218,929,548	284,855,386	217,153,948

Condensed Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
Condensed Statements of Cash Flows - USD ($) $ in Thousands	Jun. 30, 2026	Jun. 30, 2025
Cash flows from operating activities:
Net loss	$ (85,284)	$ (110,676)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	20,710	20,860
Depreciation and amortization	5,514	6,205
Net amortization/accretion on investment securities	(2,198)	(2,477)
Impairment of long-lived assets	0	2,382
Non-cash rent expense	2,149	2,277
Non-cash collaboration revenue - related party	(4,640)	0
Changes in operating assets and liabilities:
Deposit placed in escrow	23,479	(2,711)
Prepaid expenses and other current assets	143	1,242
Other long-term assets	(82)	(1,503)
Accounts payable	1,694	(758)
Accrued and other current liabilities	(2,821)	(3,488)
Operating lease liabilities	(4,245)	(3,759)
Other long-term liabilities	672	447
Net cash used in operating activities	(44,909)	(91,959)
Cash flows from investing activities:
Purchases of property and equipment	(159)	(143)
Proceeds from maturities of investments	108,427	110,300
Purchase of investments	(285,415)	(60,146)
Net cash provided by (used in) investing activities	(177,147)	50,011
Cash flows from financing activities:
Proceeds from CIRM award (Note 5)	0	6,908
Proceeds from issuance of common stock upon exercise of stock options	4	0
Proceeds from issuance of common stock under the employee stock purchase plan	450	638
Net cash provided by financing activities	208,994	19,062
Net change in cash and cash equivalents and restricted cash	(13,062)	(22,886)
Cash and cash equivalents and restricted cash — beginning of period	61,980	85,510
Cash and cash equivalents and restricted cash — end of period	48,918	62,624
Non-cash operating activities:
Property and equipment purchases in accounts payable and accrued liabilities	0	215
Supplemental disclosure:
Cash paid for amounts included in the measurement of lease liabilities	(6,528)	(6,518)
ATM Offering
Cash flows from financing activities:
Proceeds from issuance of common stock from public offering, net of commissions and issuance costs	20,668	11,516
Public offering
Cash flows from financing activities:
Proceeds from issuance of common stock from public offering, net of commissions and issuance costs	$ 187,872	$ 0

Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 38,626	$ 51,688
Short-term investments	293,978	198,522
Prepaid expenses and other current assets	7,396	7,539
Total current assets	340,000	257,749
Long-term investments	90,986	8,043
Operating lease right-of-use asset	37,739	39,888
Property and equipment, net	67,382	72,839
Deposit placed in escrow	0	23,479
Restricted cash	10,292	10,292
Other long-term assets	3,692	3,615
Total assets	550,091	415,905
Current liabilities:
Accounts payable	5,964	4,270
Accrued and other current liabilities	25,763	28,244
Total current liabilities	31,727	32,514
Lease liability, noncurrent	70,353	75,045
Other long-term liabilities	11,836	15,804
Total liabilities	113,916	123,363
Commitments and Contingencies (Notes 6 and 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 10,000,000 shares authorized as of June 30, 2026 and December 31, 2025; no shares were issued and outstanding as of June 30, 2026 and December 31, 2025	0	0
Common stock, $0.001 par value: 800,000,000 and 400,000,000 shares authorized as of June 30, 2026 and December 31, 2025, respectively; 345,345,427 and 229,413,523 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively	345	229
Additional paid-in capital	2,532,341	2,302,753
Accumulated deficit	(2,095,993)	(2,010,709)
Accumulated other comprehensive income (loss)	(518)	269
Total stockholders’ equity	436,175	292,542
Total liabilities and stockholders’ equity	$ 550,091	$ 415,905
Common stock, shares authorized (in shares)	800,000,000	400,000,000